RT Journal Article
SR Electronic
T1 International multicentre retrospective cohort study of ocular adnexal marginal zone B-cell lymphoma
JF British Journal of Ophthalmology
JO Br J Ophthalmol
FD BMJ Publishing Group Ltd.
SP 357
OP 362
DO 10.1136/bjophthalmol-2019-314008
VO 104
IS 3
A1 Hindsø, Tine Gadegaard
A1 Esmaeli, Bita
A1 Holm, Frederik
A1 Mikkelsen, Lauge Hjorth
A1 Rasmussen, Peter Kristian
A1 Coupland, Sarah E
A1 Finger, Paul T
A1 Graue, Gerardo F
A1 Grossniklaus, Hans E
A1 Honavar, Santosh G
A1 Khong, Jwu Jin
A1 McKelvie, Penelope A
A1 Mulay, Kaustubh
A1 Sjö, Lene Dissing
A1 Vemuganti, Geeta K
A1 Thuro, Bradley A
A1 Heegaard, Steffen
YR 2020
UL http://bjo.bmj.com/content/104/3/357.abstract
AB Backgrounds/aims To date, this is the largest cohort study on extranodal marginal zone B-cell lymphoma (EMZL) of the ocular adnexa (OA). The aim of the study was to characterise the clinical features of OA-EMZL.Methods A retrospective multicentre study involving seven international eye cancer centres. Data were collected from 1 January 1980 through 31 December 2017. A total of 689 patients with OA-EMZL were included.Results The median follow-up time was 42 months. The median age was 62 years (range, 8–100 years), and 55 % (378/689 patients) of patients were women. The majority of patients (82%, 558/680 patients) were diagnosed with primary OA-EMZL with Ann Arbor stage IE (90%, 485/541 patients) and American Joint Committee on Cancer stage T2 (61%, 340/557 patients) at the time of diagnosis. The orbit (66%, 452/689 patients) and the conjunctiva (37%, 255/689 patients) were the most frequently involved anatomical structures. The 5-year, 10-year and 20-year disease-specific survival (DSS) were 96%, 91% and 90%, respectively. Stage IE patients treated with external beam radiation therapy (EBRT) as monotherapy (10-year DSS, 95%) were found to have a better DSS than stage IE patients treated with chemotherapy (10-year DSS, 86%). Stage IIIE/IVE patients treated with chemotherapy and rituximab had a better DSS (10-year DSS, 96%) than stage IIIE/IVE patients treated with chemotherapy without rituximab (10-year DSS, 63%).Conclusions and relevance EMZL is a slow-growing tumour with an excellent long-term survival. Low-dose EBRT as monotherapy should be considered in localised OA-EMZL. Rituximab-based chemotherapy should be chosen in those patients with disseminated disease.